Showing 3041-3050 of 5646 results for "".
- Zeiss Acquires All Shares of Tooz, Maker of Augmented Reality Opticshttps://modernod.com/news/zeiss-acquires-tooz-maker-of-augmented-reality-and-virtual-reality-glasses/2481447/Zeiss announced it has acquired the shares of the joint venture tooz technologies, which was founded together with Deutsche Telekom in 2018 and is developer of high-tech optics in the area of augmented reality. Until now, Zeiss and Deutsche Telekom held 50% of the shares in the sta
- Alcon Launches "Alcon Experience Academy" App, Expanding On-Demand Learninghttps://modernod.com/news/alcon-launches-experience-academy-app-expanding-remote-on-demand-learning/2481422/Alcon announced the launch of the Alcon Experience Academy (AEA) app, which aims to help optimize eye care professionals’ (ECPs) digital learning experiences. The launch of the app brings AEA’s education and training resources to customers’ fingertips. The customizable
- FDA Accepts Iveric Bio's NDA and Grants Priority Review for Geographic Atrophy Drug Candidatehttps://modernod.com/news/fda-accepts-iveric-bios-nda-and-grants-priority-review-for-geographic-atrophy-drug-candidate/2481418/Iveric bio announced that the FDA has completed its filing review and accepted the company’s new drug application (NDA) for avacincaptad pegol (ACP), a novel investigational complement C5 inhibitor for the treatment of geographic atrophy (GA) secondary to age-related macular degen
- Visionix Launches Optovue Solix FullRange OCThttps://modernod.com/news/visionix-launches-optovue-solix-fullrange-oct/2481409/Visionix USA has introduced the Optovue Solix FullRange OCT in North America. Featuring 120kHz ultra-high-speed scanning, Optovue Solix FullRange OCT features anterior 18 x 6.25 scans, new posterior high-density scan patterns for more detail and better precision, int
- Bruder Healthcare Now Exclusive Licensor of "The Dry Eye Drink"https://modernod.com/news/bruder-healthcare-now-exclusive-licensor-of-the-dry-eye-drink/2481407/Bruder Healthcare, which is part of Hilco Vision, announced an exclusive licensing agreement with Dry Eye Drink LLC, the manufacturer of a portfolio of dry eye products and drink mixes formulated to provide relief for US adults suffering from symptoms of dry eye disease.
- Harrow Completes Acquisition of US Rights to Five Branded Ophthalmic Drugshttps://modernod.com/news/harrow-closes-acquisition-of-us-rights-to-ilevro-nevanac-vigamox-maxidex-and-triesence-and-will-begin-receiving-net-profit-payments-for-acquired-products/2481361/Harrow announced the closing of its previously announced acquisition with Novartis of the exclusive US commercial rights to five branded ophthalmic products: Ilevro, Nevanac, Vigamox, Maxidex, and Triesence. In December, Harrow announced it had 
- Eyenovia: Positive Evidence that Optejet Delivery Technology Decreased Inflammation From Preserved Glaucoma Solutions Compared to Dropshttps://modernod.com/news/eyenovia-positive-evidence-that-optejet-delivery-technology-decreased-inflammation-from-preserved-glaucoma-solutions-compared-to-drops/2481349/Eyenovia announced results from a research study conducted in collaboration with Pedram Hamrah, MD, Interim Chairman of Ophthalmology at Tufts Medical Center, which evaluated the gene and protein expression of cytokines and chemokines after latanoprost+benzalkonium chloride (BAK) treatm
- AcuFocus Announces First Commercial Patients Treated With the IC-8 Apthera IOLhttps://modernod.com/news/acufocus-announces-first-commercial-patients-treated-with-the-ic-8-apthera-iol/2481329/AcuFocus announced that Vance Thompson, MD, of Vance Thompson Vision, Sioux Falls, South Dakota has commercially implanted the first patients with the IC-8 Apthera IOL. The first and only small aperture, non-toric extended depth of focus IOL, the Apthera IOL is FDA approved fo
- Elios Vision Announces Registration of Elios in the United Kingdomhttps://modernod.com/news/elios-vision-announces-registration-of-elios-in-the-united-kingdom/2481318/Elios, a technology used to treat glaucoma at the same time as cataract surgery, is now registered for use in the United Kingdom, according to Elios Vision. The Elios does not require an implant and is designed to provide long-lasting results that may free patients and th
- Orasis Pharmaceuticals Submits NDA for Investigational Novel Eye Drop Candidate, CSF-1, for the Treatment of Presbyopiahttps://modernod.com/news/orasis-pharmaceuticals-submits-nda-for-investigational-novel-eye-drop-candidate-csf-1-for-the-treatment-of-presbyopia/2481315/Orasis Pharmaceuticals announced that it has submitted a new drug application (NDA) to the FDA for investigational CSF-1 (low dose pilocarpine hydrochloride 0.4%). "This NDA submission is a significant milestone for Orasis as we advance CSF-1 towards commercialization and